Societe Generale, Prudential and others buy 3% stake in Anthem Biosciences for Rs 1,275 cr
What's the deal? Global investors including Societe Generale and Prudential Hong Kong, alongside Indian mutual funds and insurance companies, have acquired a 3% stake in Anthem BiosciencesDealroom has a profile for this one. Try Dealroom → through a secondary transaction worth Rs 1,275 crore (roughly $150M).
The deal, announced in June 2026, brings together a mix of international financial institutions and domestic Indian investors backing the biosciences firm.
Why now? The secondary nature of the transaction suggests existing shareholders sought liquidity rather than the company needing fresh capital. India's contract research and biosciences sector has attracted growing interest from global institutional investors looking to diversify beyond traditional tech bets.
What could go wrong? Secondary deals at high valuations can signal frothy pricing if the underlying business doesn't grow into its implied valuation. With multiple investor types — from European banks to Hong Kong insurers to Indian mutual funds — alignment on long-term strategy could prove tricky.
The signal: Anthem Biosciences, a late-stage contract research, development, and manufacturing services firm, is drawing the kind of diversified institutional capital — from corporate investors like Societe Generale to domestic Indian funds — that typically clusters around pre-IPO assets. The willingness of global corporates to enter via secondary stakes rather than a primary raise suggests confidence in the company's trajectory and hints that a public listing could be on the horizon.
Read more: article.wn.com
